EFFECT OF BASELINE EPO AND PRIOR ERYTHROPOIESIS STIMULATING AGENTS ON RBC TRANSFUSION INDEPENDENCE IN LOW-/INT-1-RISK MDS WITH DEL5Q TREATED WITH LENALIDOMIDE: A RANDOMIZED PHASE 3 STUDY (MDS-004)

被引：0
|
作者：
Fenaux, P. [1 ]
Giagounidis, A. [2 ]
Selleslag, D. [3 ]
Knight, R. [4 ]
Fu, T. [4 ]
Hellstrom-Lindberg, E. [5 ]
机构：
[1] Univ Paris 13, Hop Avicenne, Bobigny, France
[2] St Johannes Hosp, Duisburg, Germany
[3] AZ St Jan Brugge AV, Brugge, Belgium
[4] Celgene Corp, Summit, NJ USA
[5] Karolinska Univ, Huddinge Hosp, Stockholm, Sweden
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0311
引用
收藏
页码：125 / 125
页数：1
相关论文
共 44 条
  • [31] Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive
    Steensma, David P.
    Platzbecker, Uwe
    Van Eygen, Koen
    Raza, Azra
    Santini, Valeria
    Germing, Ulrich
    Font, Patricia
    Samarina, Irina
    Diez-Campelo, Maria
    Thepot, Sylvain
    Vellenga, Edo
    Patnaik, Mrinal M.
    Jang, Jun Ho
    Bussolari, Jacqueline
    Sherman, Laurie
    Sun, Libo
    Varsos, Helen
    Rose, Esther
    Fenaux, Pierre
    BLOOD, 2018, 132
  • [32] CLINICAL FACTORS PREDISPOSING TO ACHIEVEMENT OF RBC TRANSFUSION INDEPENDENCEIN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES) WITHOUT DEL(5q) IN MDS-005 STUDY
    Santini, V.
    Li, J. Shiansong
    Swern, A. S.
    Almeida, A.
    Giagounidis, A.
    Fu, T.
    Sanna, A.
    Hoenekopp, A.
    Beach, C. L.
    Skikne, B.
    Fenaux, P.
    HAEMATOLOGICA, 2015, 100 : 3 - 4
  • [33] Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
    Santini, Valeria
    Almeida, Antonio
    Giagounidis, Aristoteles
    Groepper, Stefanie
    Jonasova, Anna
    Vey, Norbert
    Mufti, Ghulam J.
    Buckstein, Rena
    Mittelman, Moshe
    Platzbecker, Uwe
    Shpilberg, Ofer
    Ram, Ron
    del Canizo, Consuelo
    Gattermann, Norbert
    Ozawa, Keiya
    Risueno, Alberto
    MacBeth, Kyle J.
    Zhong, Jianhua
    Seguy, Francis
    Hoenekopp, Albert
    Beach, C. L.
    Fenaux, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2988 - +
  • [34] PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY OF SINTRA-REV CLINICAL TRIAL, LENALIDOMIDE VS PLACEBO PHASE 3 STUDY IN LOW/INT-1 MDS PATIENTS WITH DEL(5Q) AND TRANSFUSION INDEPENDENCY
    Lopez Cadenas, F.
    Xicoy, B.
    Bargay, J.
    Sanz, G.
    Amigo, M. L.
    Arrizabalaga, B.
    Bernal, T.
    De Paz, R.
    Sanchez, J.
    Nomdedeu, B.
    Hernandez Rivas, J. A.
    Fenaux, P.
    Slama, B.
    Giagounidis, A.
    Lumbreras, E.
    Thepot, S.
    Platzbecker, U.
    Coll, R.
    Redondo, A.
    Fernandez Roldan, M. C. Del Canizo
    Diez-Campelo, M.
    HAEMATOLOGICA, 2017, 102 : 484 - 485
  • [35] Phase 3 Study of Lenalidomide vs Placebo in Non-Transfusion Dependent Low Risk del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 17 - 18
  • [36] Phase 3 Study of Lenalidomide Vs Placebo in Non-Transfusion Dependent Low Risk MDS Del(5q) Patients: Preliminary Blinded Analysis of the European SINTRA-REV Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 14 - 15
  • [37] Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial
    Cadenas, Felix Lopez
    Lumbreras, Eva
    Xicoy, Blanca
    Sanchez, Joaquin
    Coll, Rosa
    Slama, Bohrane
    Hernandez-Rivas, Jose Angel
    Thepot, Sylvain
    Bernal, Teresa
    Arrizabalaga, Beatriz
    Guerci-Bresler, Agnes
    Sanz, Guillermo F.
    Bargay, Joan
    Amigo, Maria Luz
    de Paz, Raquel
    Nomdedeu, Benet
    Giagounidis, Aristoteles
    Platzbecker, Uwe
    Wickenhauser, Stefan
    Gotze, Katharina S.
    Arar, Ali
    Rivas, Jesus Maria Hernandez
    Fenaux, Pierre
    Del Canizo, Consuelo
    Diez-Campelo, Maria
    BLOOD, 2020, 136
  • [38] STUDY PHASE 3 OF LENALIDOMIDE (LEN) IN PATIENTS (PTES) WITH MYELODYSPLASTIC SYNDROME (SMD) WITHOUT DEL(5Q) OF LOW RISK AND WITH TRANSFUSIONAL DEPENDENCE (DT), REFRACTORIES OR NON RESPONSIVE TO STIMULATING AGENTS OF ERYTHROPOIESIS
    Del Canizo, M. C.
    Almeida, A.
    Giagounidis, A.
    Fenaux, P.
    Santini, V
    Ozawa, K.
    HAEMATOLOGICA, 2015, 100 : 149 - 149
  • [39] Effect of Lenalidomide (LEN) Exposure on AML-Free Survival and Overall Survival in LEN-Treated Patients (Pts) with IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS) with Del(5q)
    Sekeres, Mikkael A.
    Swern, Arlene S.
    List, Alan F.
    Fenaux, Pierre
    Sogrue, Mary M.
    BLOOD, 2015, 126 (23)
  • [40] Durable Continuous Transfusion Independence (TI) with Imetelstat in IMerge Phase 3 for Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents (ESAs)
    Platzbecker, Uwe
    Komrokji, Rami S.
    Zeidan, Amer M.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    Savona, Michael R.
    Madanat, Yazan F.
    Jonasova, Anna
    Illmer, Thomas
    Sherman, Laurie
    Berry, Tymara
    Riggs, Jennifer
    Xia, Qi
    Navada, Shyamala
    Wan, Ying
    Huang, Fei
    Feller, Faye M.
    Santini, Valeria
    BLOOD, 2023, 142
12345